Depletion of ACE2 and the subsequent imbalance of the ACE/ACE2 metabolic pathways may thus impair both serotonin and dopamine synthesis, resulting in higher rates of mental “fog,” depression, and anxiety in COVID-19 patients. This evidence concerns the gene ACE2 and depressive symptom measurement.